Other drugs acting on the same DNA damage response pathway, such as ATR inhibitors, have shown more promise in ovarian cancer [42], and are being investigated as potentiators of immune checkpoint blockade [43–46], which are otherwise often ineffective on their own [47]. The gene discussed is ATR; the disease is ovarian carcinoma.